News Release 

Special Focus Issue highlights genetic and genomic education for personalized medicine

Special Focus Issue of Personalized Medicine highlights the importance and latest strategies of genetic and genomic education

Future Science Group

The Future Science Group (FSG) published journal, Personalized Medicine, has announced the release of a Special Focus Issue entitled 'Improving Genomics Education' that highlights the implementation of genetics and genomics education for healthcare providers and the general public.

Personalized Medicine was delighted to welcome the journal's Associate Editors Jeanette McCarthy, Associate Professor of Medicine at the University of California (CA, USA) and George Patrinos, Professor of Pharmacogenomics and Pharmaceutical Biotechnology at the University of Patras (Greece) as Guest Editors for the Special Focus Issue.

"Genetic tests are only as effective as the healthcare providers who use them. Efforts to educate users should go hand-in-hand with developing the tools for Personalized Medicine," explained McCarthy.

Patrinos added: "Success in Personalized Medicine implementation depends not only on enriching healthcare professionals genomics education but also raising the general public's genetics awareness - it takes two to tango!"

Highlights from the issue include a Research Article investigating provider engagement of genetic education in oncology; a Special Report highlighting the trends, challenges and importance of undergraduate medical education in genetics and genomics; as well as an Interview with Carla Easter (National Institutes of Health; MD, USA) discussing educating the public on genetics and genomics.

Ebony Torrington, Commissioning Editor for Personalized Medicine, further added: "I am delighted with the response already received from experts in the field regarding the release of this Special Focus Issue. It has been a pleasure to work with both Jeanette McCarthy and George Patrinos to produce such an insightful issue that we hope will benefit the field and ultimately lead to improved patient care in the future."

###

The Guest Editors' free-access Foreword article is available online here: https://www.futuremedicine.com/doi/10.2217/pme-2019-0025

The full issue is available online here: https://www.futuremedicine.com/toc/pme/16/3

About Personalized Medicine

Personalized Medicine (ISSN 1741-0541) is a Medline-indexed journal that translates recent genomic, genetic and 'omic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape the future of medicine by providing a platform for expert commentary and analysis.

Personalized Medicine covers the translation of research discoveries into the clinic and reports on fields that are less well-represented in Personalized Medicine literature, such as implementation science, precision public health and outcomes research. Articles submitted to Personalized Medicine are subject to rigorous peer review. The journal offers an open access option and, through our accelerated publication route, can provide publication in as little as 6 weeks from submission.

About Future Science Group

Founded in 2001, Future Science Group is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. Future Science Group's portfolio consists of three publishing imprints, Future Science, Future Medicine, Newlands Press, as well as a content development imprint, PharmaPlatforms. In addition to a core business of subscription and open access journal publishing, Future Science Group develops specialist knowledge networks and content hubs, enabling professionals to easily connect and collaborate with their peers in niche scientific fields.

The aim of Future Science Group is to serve the advancement of clinical practice and drug research by enhancing the efficiency of communication among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.future-science-group.com

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.